Clinical trial · Interventional
Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma
Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT
NCT02515084CI-TRIAL-00023635THYRIRMTEPcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the concordance between the 18F-PET/CT under thyrotropin stimulation and the diffusion-weighted Magnetic Resonance Imaging, in the detection of residual mass in 40 patients with partial response or relapsed differentiated thyroid carcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapse | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI imaging | Device | — | UNRESOLVED |
| PET | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-FDG-PET and dw-MRI
- description
- At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed
- interventionNames
- Device: PET
- Device: MRI imaging
Primary outcomes (1)
- measure
- Report of positive or negative results of detection of recurrent lesions from both dw-MRI and 18F-FDG PET/CT. data will be reported extensively and descriptively.
- timeFrame
- 1 year
- description
- To assess concordance between FDG PET-CT scan and MRI in detection of cervical residual masses in 40 patients in Partial Response or in relapse cervical well-differentiated thyroid carcinoma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female, * Subjects must be 18 years of age or older, * Histologically confirmed papillary or follicular differentiated thyroid carcinoma with partial response or complete response, defined by * Thyroglobulin \> 2 μg/L under thyrotrophin stimulation, four months after at least two 131-I based treatments (3,7 GBq/100mCi or more if optimal conditions), * Negative extension assessment (total body bone scan, (3,7 GBq/100 mCi or more)), echography, CT scan ( neck, thorax, abdomen): no findings.. * Patient's Informed Consent form signed. Exclusion Criteria: * History of previous cancer within the least three years, * Performance Status \> 2, * Protected adults * Any medical, psychological, social or disabling conditions that could interfere or jeopardize the patient's participation * History of allergy to radio-iodine, * Estimated GFR \< 45 ml/min /m² (MDRD method), * Women of childbearing potential without contraceptive method, * Uncontrolled diabetes mellitus, * Hypersensitivity to FDG or to any radio-tracers, * Contraindication to administration of Thyrogen® 0.9mg * Intraocular foreign bodies or any metallic foreign bodies that contraindicates the MRI. * Vascular clips, any object or implanted device that could interact with the ferromagnetic field, * Coronary and peripheral clips, aortic stent grafts, prosthetic heart valves, annuloplasty rings, vena cava filters, cardiac pacemaker, implantable cardiovascular defibrillators...., * Implanted insulin infuser * Neurostimulator device * Claustrophobia * Agitation or psychological trouble
References
Publications (0)
Data not yet available
No reference posted for this study.